BeiGene | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Beigene Study ID

BGB-A317-A445-101

ClinicalTrials.gov ID

NCT04215978

EudraCT Number

2022-501177-39-00

China Drug Trials ID

CTR20220453

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents